Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 21,040 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Covid19
Interventions: Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin; Drug · Other
Lead sponsor: Susanna Naggie, MD; Other
Eligibility: 30 Years and older
Enrollment: 10,956 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 110
States / cities: Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more

Conditions: Neovascular Age-related Macular Degeneration
Interventions: Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years and older
Enrollment: 561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 55
States / cities: Mesa, Arizona • Sun City, Arizona • Campbell, California + 51 more

Conditions: Multiple System Atrophy, Parkinsons Disease
Interventions: Sural Nerve Graft to the Substantia Nigra, Sham surgery; Procedure
Lead sponsor: Craig van Horne, MD, PhD; Other
Eligibility: 40 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Laparoscopic Hysterectomy and/or Laparoscopic Sacrocolpopexy
Interventions: Fleet Enema (sodium biphosphate and sodium phosphate); Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Head and Neck Cancer
Interventions: ENI using IMRT with or without chemotherapy, INRT, ENI; Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Postoperative Urinary Retention
Interventions: Tamsulosin, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 35 Years and older · Male only
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Preeclampsia With Severe Features
Interventions: Nifedipine XL; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA), Placebo; Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 1,586 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more

Conditions: Advanced Malignancies
Interventions: Tanespimycin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiopulmonary, Exercise
Interventions: COSMED K5 CPET (Cardiopulmonary Exercise Test), ParvoMedics CPET; Device
Lead sponsor: Baylor Research Institute; Other
Eligibility: 20 Years to 29 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Frisco, Texas

Conditions: Post Liver Transplantation Weight Gain, Post Liver Transplantation Obesity, Nonalcoholic Steatohepatitis
Interventions: Dietary and life style modification; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: Project Dulce + Dulce Digital; Behavioral
Lead sponsor: Scripps Whittier Diabetes Institute; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: El Cajon, California • Denver, Colorado

Conditions: Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Sickle Cell Hemoglobin C Disease, Pain Crisis
Interventions: Buprenorphine Buccal Film [Belbuca]; Drug
Lead sponsor: Natasha Archer; Other
Eligibility: 12 Years to 22 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bicep Tendinitis, Biceps; Tenosynovitis, Bicipital Tendinitis, Left Shoulder, Bicipital Tendinitis, Right Shoulder, Bicipital Tendinitis, Unspecified Shoulder, Biceps Tendon Disorder
Interventions: Dry Needling, Heavy Slow Load Exercise, Rotator cuff and scapular stabilization exercise program, Soft tissue mobilization; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Aurora, Colorado • Boulder, Colorado

Conditions: ER+ Breast Cancer, Breast Cancer, Aromatase Inhibitors
Interventions: White Wine, Grape Juice; Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 21 Years to 90 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Arterial Hypertension
Interventions: Fulvestrant; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pain, Back, Spinal Stenosis, Disc Herniation, Spondylosis, Spondylolisthesis, Back Injuries
Interventions: ACT intervention; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 22 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Healthy
Interventions: Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp), MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.], MVA-BN-Filo 5*10^7 Inf. U., Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 525 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Acute Respiratory Distress Syndrome
Interventions: Aspirin, Lactose powder; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 16
States / cities: Stanford, California • Bridgeport, Connecticut • Gainsville, Florida + 11 more

Conditions: Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Digital Health Coaching Program, Fitbit; Behavioral · Device
Lead sponsor: Pack Health; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Houston, Texas • Seattle, Washington

Conditions: Acute Leukemia, Chronic Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions: Nivolumab (.25 mg/kg), Tocilizumab, Nivolumab (.5 mg/kg); Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Convergence Insufficiency
Interventions: office-based vergence/accommodative therapy; Procedure
Lead sponsor: Salus University; Other
Eligibility: 9 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lymphedema
Interventions: Aquatic Exercise arm; Behavioral
Lead sponsor: Baylor Research Institute; Other
Eligibility: 21 Years to 90 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Placebo, RSV preF Protein 50 mcg, RSV preF Protein 150 mcg, Ad26.RSV.preF 1*10^11 vp, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg, Selected Regimen; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 669 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Search by objective public record fields.

ACTIV-6: COVID-19 Study of Repurposed Medications

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies

Mechanical Bowel Preparation Before Laparoscopic Hysterectomy and Laparoscopic Sacrocolpopexy: a Randomized Controlled Trial

Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy

Trial of Prophylactic Tamsulosin for Postoperative Urinary Retention in Primary Total Hip and Knee Arthroplasty Patients

Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI)

A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin

COSMED K5 Validation and Reliability Study

Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity

Project Dulce for Arab Americans With Type 2 Diabetes

Buprenorphine for the Management of Pain in Children With Sickle Cell Disease

Dry Needling and Exercise Versus Traditional Physical Therapy for Biceps Tendinitis

Alcohol and Breast Cancer (ABC) Trial

Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension

PREventing Pain After Surgery

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

LIPS-A: Lung Injury Prevention Study With Aspirin

Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab

Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

Objective Assessment of Disparity Vergence After Treatment of Symptomatic CI in Children

Aquatic Exercise Study for Breast Cancer Patients With Lymphedema

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older